JPMorgan analyst Eric Joseph upgraded Vir Biotechnology to Overweight from Neutral with a price target of $34, down from $35. The analyst sees an "appreciable commercial opportunity" for VIR-2482 within the high-risk, older adult population. Positive PENINSULA data for flu prevention mid-year should be a "rather linear read-through" from a younger Phase 2 study population and creates "attractive upside potential," the analyst tells investors in a research note. Moreover, the firm believes mRNA platform candidates are showing "limited differentiation" over inactivated egg-based incumbents. It says Vir shares "meaningfully under-reflect" the VIR-2482 flu and HBV franchises on a risk adjusted basis.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VIR:
- 3 Stocks to Buy Today, 3/6/2023, According to Top Analysts
- Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
- Vir Biotechnology reports Q4 EPS (76c), consensus (39c)
- Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
